Therapeutic Efficacy Of Artemether Lumefantrine With (S) Primaquine For The Treatment Of Uncomplicated Plasmodium Falciparum In Bambasi District, Benishangul-Gumuz, Ethiopia

Abstract

The Therapeutic Efficacy And Safety Of Standard Artemether-Lumefantrine Plus Single Dose Primaquine For The Treatment Of Uncomplicated Plasmodium Falciparum Is Not Yet Assessed And Poorly Documented In Bambasi, North Western Ethiopia. As Per The Recommendation Of World Health Organization Every Two Year, Regular Monitoring Of Antimalarial Drug Efficacy Is An Important Tools Of Supporting National Malaria Treatment Policy. The Study Was Investigated The Efficacy And Safety Of Al Plus (S) Pq Treatment For P. Falciparum Malaria In Ethiopia. One Arm Longitudinal Prospective, Evaluated Clinical, Safety And Parasitological Response, Directly Observed Treatment During 42 Days Of Follow Up Visits With Al Plus (S) Pq For 6 Months And Older Ages Of Participants With Uncomplicated P. Falciparum Malaria In Bambasi District, Ethiopia. A Study Was Based On An Updated Protocol Of World Health Organization 2009 Recommendations For The Surveillance Of Anti-Malarial Drug Efficacy With Primary Outcomes Of Clinical And Parasitological Cure Rate Were At Day-42. The Secondary Outcomes, Safety, Fever, Asexual Parasite And Gametocyte Clearance Were Assessed. The Cure Rate At Day-42 Of Microscopy And Pcr Were Compared Using Per-Protocol (Pp) Analysis. Nested Polymerase Chain Reaction (Npcr) Was Used For Confirmatory Test. While Msp2-Npcr Used For Pcr Correction And P. Falciparum Parasite Genotyping Of Baseline And At The Time Of Recurrences To Distinguish Between True Treatment Failure (Recrudescence) And New Infections. Of The 123 Enrolled Study Participants, 52 Completed Day-42 With Acpr, 14 Loss To Follow Up And 57 Individuals With Parasite Reoccurrences Onwards From Day-14 With Falciparum, Mixed And P. Vivax Infections. A Pair Of 41 Samples Of Falciparum Infections Were Msp2-Pcr-Genotyped And 14.3% Treatment Failure (12 Recrudescence) Was Observed Using Who Kaplan-Meier Survival Estimation. The Per-Protocol (Pp) Cure Rate Of Al Plus (S) Pq Of Pcr-Uncorrected And Pcr Correction Were 55.2% (95% Ci 44.8-64.4) And 85.7% (75.8-91.7%) Respectively. While 22.5% (12) Of The Parasite Recurrences Were P.Vivax Co-Infections Contribute For Microscopic Treatment Failure. In This Finding, Delayed Parasite Clearance Rate Was Observed Whereas Gametocyte Was Exponentially Decreased And Cleared After Day-3 Visiting. The Delayed Asexual Parasite Clearance Is A Good Indicator Of Either Partial Or Multi-Drug Resistance. A Large Scalemolecular Surveillance To Assess The Possible Mechanisms Of Artemisinin-Tolerate Parasites In The Area Is Advised To Provide More Information.